Respiratory Tract Infection Treatment Market
- Size, Share, trends, and Forecast to 2026
Respiratory tract infection is any infection in the nose, sinuses around the nose, throat (pharynx),
voice box (larynx), and windpipe (trachea), airways (bronchi) or lungs, which may occur anytime,
usually beginning with cold. This infection is usually caused by bacteria and viruses. Virus prone
respiratory tract infection are easily transmitted and very contagious while bacterial infection can
also be developed during the course of an upper respiratory tract infection. Respiratory tract
infection is generally divided into two categories- upper respiratory tract infection (infection in
nose, throat, and pharynx) and lower respiratory tract infection (infection below the larynx).
Download PDF Brochure Of This Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/2030
Market Dynamics
The global respiratory tract infection market is expected to witness lucrative growth due to factors
such as increasing prevalence of lung diseases, surge in geriatric population, and rising risk of
pneumonia in children. According to the World Health Organization (WHO), respiratory syncytial
virus (RSV) is responsible for around 30 million lower respiratory tract infection cases in children
worldwide. The prevalence of such viral diseases is expected to drive growth of the global market
over the forecast period.
Increasing air pollution can severely affect respiratory health of children as well as adults. Various
studies have shown effects of air pollution that can exacerbate existing respiratory conditions such
as asthma, COPD, and upper airway allergies.
However, adverse effects of using NSAIDs and antibiotics on patients suffering from respiratory
tract infection may hinder growth of the market. In 2015, the U.S. Food and Drug Administration